An interesting study conducted by Guarducci et al. showed that the ratio of cyclin E1 to RB1 level (not only cyclin E1 amplification and RB1 loss) is a poor prognostic factor and predicts palbociclib de novo resistance in HR+ breast cancer [26]. Here, RB1 is linked to breast carcinoma.